Evidence map›Paper›PMID 27708551›Full record

ArticleCancer cell international2016

Bone morphogenetic protein 2 (BMP2) induces growth suppression and enhances chemosensitivity of human colon cancer cells.

Radhakrishnan Vishnubalaji, Shijun Yue, Musaad Alfayez, Moustapha Kassem, Fei-Fei Liu, Abdullah Aldahmash, Nehad M Alajez

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Radhakrishnan VishnubalajiStem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, 11461 Kingdom of Saudi Arabia.
Shijun YuePrincess Margaret Cancer Centre, University Health Network, Toronto, ON Canada.
Musaad AlfayezStem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, 11461 Kingdom of Saudi Arabia.
Moustapha KassemMolecular Endocrinology Unit (KMEB), Department of Endocrinology, University Hospital of Odense and University of Southern Denmark, Odense, Denmark.
Fei-Fei LiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON Canada.
Abdullah AldahmashStem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, 11461 Kingdom of Saudi Arabia ; Prince Naif Health Research Center, King Saud University, Riyadh, 11461 Kingdom of Saudi Arabia.
Nehad M AlajezStem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, 11461 Kingdom of Saudi Arabia.
King Saud University · SAPrincess Margaret Cancer Centre · CAUniversity Health Network · CAUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular profiling of colorectal cancer (CRC) based on global gene expression has revealed multiple dysregulated signalling pathways associated with drug resistance and poor prognosis. However, the role of BMP2 signaling in CRC is not fully characterised.

methodsBioinformatics data analysis were conducted on the GSE21510 dataset. Leniviral technology was utilized to stably express BMP2 in the HCT116 CRC model. Gene expression profiling was conducted using Agilent microarray platform while data normalization and bioinformatics were conducted using GeneSpring software. Changes in gene expression were assessed using qRT-PCR. AlamarBlue assay was used to assess cell viability in vitro. In vivo experiments were conducted using SCID mice.

resultsOur data revealed frequent downregulation of BMP2 in primary CRC tissues. Additionally, interrogation of publically available gene expression datasets revealed significant downregulation of BMP2 in metastatic recurrent compared to non-metastatic cancer (p = 0.02). Global gene expression analysis in CRC cells over-expressing BMP2 revealed multiple dysregulated pathways mostly affecting cell cycle and DNA damage response. Concordantly, lentiviral-mediated re-expression of BMP2 inhibited HCT116 CRC growth, sphere formation, clonogenic potential, cell migration, and sensitized CRC cells to 5-fluorouracil (5-FU) in vitro. Additionally, BMP2 inhibited CRC tumor formation in SCID mice.

conclusionsOur data revealed an inhibitory role for BMP2 in CRC, suggesting that restoration of BMP2 expression could be a potential therapeutic strategy for CRC.

Indexed as

Bone morphogenetic protein2 (BMP2)ChemosensitivityColon cancer

Identifiers

PMID27708551
PMCPMC5043592
OpenAlexW2524784007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.